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Abstract: New and diverse groups of noncoding RNAs are beginning to be discovered. These noncoding RNAs are grouped based
on their sizes, genomic positions, or distinctive functions ranging from the regulation of chromatin structure and gene expression to
genome stability maintenance. Among noncoding RNAs, microRNAs are the best studied and understood small RNAs with direct and
indirect roles in normal and in cancer cells. Given the high rate of transcription from noncoding parts of the genome, other noncoding
elements are also of great interest. It is also of interest to understand that there may be interesting cases of crosstalk and/or coregulation
between the noncoding and the coding portion of the genome. Therefore, deregulated expression of noncoding RNAs can be considered
to cause significant alterations in cancer cells. The complexities of the genome and transcriptome still remain mesmerizing. As we better
understand these complexities, we will be able to improve our understanding of human conditions and will hopefully develop tools to
improve the ways in which we deal with diseases, particularly cancer. Here, based on recent findings, we provide a descriptive profile of
noncoding RNA classes, their roles, and their potential contributions to the complex events of tumorigenesis.
Key words: Noncoding RNAs, cancer, long noncoding RNAs, small noncoding RNAs, microRNAs

1. Introduction
Following the completion of the human genome a decade
ago, we came across a surprisingly low number of proteincoding genes in the human genome compared to the initial
predictions. The low number of protein-coding genes,
corresponding to only 2% of the human genome, was
surprising, because it meant that we were undervaluing the
potential roles of alternative promoter usage, alternative
splicing, alternative polyadenylation, and so on to explain
the vast diversity of proteins in cells. It was also a realization
that the rest of the genome must also have some role, either
structural or functional. Indeed, over the years, studies
have documented widespread transcription across 70%–
90% of the genome with approximately 9000 small RNAs,
1100 microRNAs (miRNAs; http://microRNA.org), 32,000
long noncoding RNAs (lncRNAs), and 11,000 expressed
pseudogenes (Bernstein et al., 2012; Volders et al., 2013).
Based on increasing evidence, it has become clear that
this nonprotein-coding portion of the genome is critical
in managing the greater complexity of higher eukaryotes
during development and in different physiological and/
or disease states, especially cancer. While most of the
focus is on miRNAs as small noncoding RNAs, other
long or small noncoding RNAs are attracting attention in
normal and in cancer cells. Here we provide an overview
* Correspondence: erson@metu.edu.tr

of currently known noncoding RNA elements (Figure 1),
their functions, and their connections with disease states,
especially cancer (Table). In the first part, lncRNAs and
their subclasses will be discussed. The second part focuses
on small noncoding RNAs.
2. Long noncoding RNA classes
lncRNAs are transcripts of longer than ~200 nucleotides
with little or no protein-coding capacity (it is possible
that some lncRNAs encode small peptides). In humans,
with exceptions, lncRNAs are generally polyadenylated
and are spliced to generate a small number of exonic
regions (Derrien et al., 2012). On the other hand, evidence
suggests some lncRNAs to be processed and stabilized by
other mechanisms such as RNase P cleavage to generate a
mature 3’ end, capping by snoRNP complexes at both ends,
or formation of circular structures (Zhang et al., 2013a).
The lncRNA genes are positioned throughout various
chromosomal regions of the genome. Therefore, the
accepted classification of lncRNAs is generally based on
their locations, whether they are intergenic, intronic,
or found in the antisense strand [also known as natural
antisense transcripts (NATs)] or upstream to annotated
protein-coding genes. With the advancements of
sequencing methods, along with other noncoding RNAs,
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Figure 1. Noncoding RNA classes. Based on size, noncoding RNAs can be divided into long or small
noncoding RNAs. Further subgroups are based on genomic positions, structures, or functions.
Table. Noncoding RNAs associated with diseases.
Name

Class

Disease

PCA3

lincRNA

Prostate

CDKN2B-AS1

antisense ncRNA-cis

Susceptibility for cardiovascular
diseases, cancer, Alzheimer disease

BACE1-AS

antisense ncRNA-cis

Alzheimer disease

MALAT1

intergenic lncRNA

Nonsmall cell lung cancer

HOTAIR

antisense intergenic
RNA-trans

Various cancers

Bridging chromatin with chromatinmodifying proteins, especially with the
polycomb repressive complexes

Nahkuri and Paro, 2012

XIST

lncRNA

Various, myelodysplastic syndrome

Nuclear compartmentalization and
propagation of H3K27 methylation, X
inactivation

Yildirim et al., 2013

15q11–q13 snoRNAs

snoRNA

Prader–Willi syndrome

Associate strongly with Fox family
splicing regulators and alter patterns of
splicing

Yin et al., 2012

PRNCR1 and
PCGEM1

lncRNAs

Prostate cancer

Enhancer-derived, leads to activation of
androgen receptor

Yang et al., 2013

PTENP1

lncRNA

Various cancers

Pseudogene of PTEN, microRNA
sponge

Poliseno et al., 2010

HULC

lncRNA

Hepatocellular carcinoma

microRNA sponge to downregulate
miRNA-372

Panzitt et al., 2007; Wang
et al., 2010

Lethe

lncRNA

Inflammatory signaling

Pseudogene transcribed by NF-kB

Rapicavoli et al., 2013

818

cancer

Function

Reference

Overexpressed/biomarker potential

Sartori and Chan, 2014

Epigenetic silencing of INK4 locus

Yu et al., 2008; Yap et al.,
2010

Increased stability of BACE1 mRNA
and protein
Alternative splicing and epigenetic
regulation

Faghihi et al., 2008
Ji et al., 2003; Tripathi et
al., 2010; Yang et al., 2011b
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lncRNA discovery has immensely accelerated. It turns out
that lncRNA expression is tightly controlled in a spatial,
temporal, cell-type specific manner suggesting functional
relevance.
Given the vast number of lncRNAs in the genome,
delineating the function of lncRNAs is a topic of great
interest. Among various examples of lncRNA functions
(splicing, translation, etc.), it seems that lncRNAs exert
their main functions by providing a kind of guidance
mechanism for directing epigenetic changes to the
chromatin structure (Figure 2). lncRNAs can modulate
chromatin architecture by binding to complementary
sequences of partially single-stranded chromosomal DNA
or nascent transcripts. Upon this interaction, chromatinmodifying proteins such as trithorax or polycomb groups
of proteins can be recruited to the site where epigenetic
alterations such as DNA methylation, nucleosome
position changes, and histone modifications will take place
(Nahkuri and Paro, 2012). This way, lncRNAs can function
as adaptors that aid in linking specific chromatin loci with
chromatin-remodeling complexes as well as transcription
factors. In addition, they can bind to transcription
factors as decoys (Rapicavoli et al., 2013) to regulate their
interactions with DNA or to miRNAs and act as sponges
so that a specific pool of miRNAs fail to bind to the target
mRNAs, etc.

lncRNAs are also emerging as important regulators
of immune cell differentiation and activation in innate
and adaptive immunity pathways (Fitzgerald and Caffrey,
2014). As we improve our understanding of how lncRNAs
function, it seems there will be exciting developments in
the field of cancer diagnosis and therapeutics. A promising
example is the overexpressed prostate cancer gene 3
(PCA3) lncRNA that may prove to be better than existing
biomarkers for prostate cancer (Sartori and Chan, 2014).
Significant effort has been focused on new discovery
of lncRNAs and their expression profiles. Studies so far
also provided functional evidence on the mechanism of
lncRNA actions. Several lncRNAs whose functions are
validated experimentally can be listed as XIST (X inactivespecific transcript), HOTAIR (HOX transcript antisense),
and HULC (highly upregulated in cancer) (Volders et al.,
2013). Here we will try to summarize recent literature
on exemplary lncRNAs based on a classification of their
genomic positions.
2.1. Linear lncRNAs
2.1.1. Antisense lncRNAs (also known as natural
antisense transcripts)
LncRNAs that reside on opposite strands of protein-coding
genes are called NATs and named after the protein-coding
gene with an “-AS” suffix according to the HUGO Gene

Figure 2. A- LncRNAs can bind to regions of ssDNA to form a DNA-RNA heteroduplexes, or to dsDNA to form
triplexes (DNA-DNA-RNA). B- lncRNAs can be tethered to a chromatin through association with chromatinmodifying proteins and/or transcription factors. C- lncRNAs can act as RNA decoys (e.g., Lethe). D- lncRNAs can take
roles in RNA splicing/translation (e.g., sno-lncRNAs). E- lncRNAs in the form of endogenous competitors can bind to
microRNAs and alter their mRNA target interactions.
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Nomenclature Committee. NATs can act in cis or in trans.
A cis-NAT overlaps with its complementary gene, whereas
a trans-NAT does not overlap with its complementary gene.
CDKN2B-AS1 (also known as ANRIL, antisense ncRNA
in the INK4 locus) is an example of a cis-acting lncRNA.
Mouse and human fibroblast studies showed combined
binding of polycomb proteins and ANRIL to lead to
epigenetic silencing of the INK4 locus (Yu et al., 2008; Yap
et al., 2010). BACE1-AS is another cis-acting lncRNA that
is antisense to the BACE1 gene that codes the β-secretase-1
enzyme. The BACE1-AS increase in Alzheimer disease may
contribute to the increased stability of BACE1 mRNA and
protein, which is a crucial enzyme in Alzheimer disease
pathophysiology (Faghihi et al., 2008).
Trans-acting NATs (i.e. complementary to a
nonoverlapping region in the genome) exist as well.
Examples of trans-acting NAT will be discussed below.
2.1.2. Intergenic lncRNAs
A well-studied example of an intergenic lncRNA
(lincRNA) is MALAT1 (metastasis-associated lung
carcinoma transcript 1), which is ubiquitously expressed
and localized to the nucleus in normal tissues, and it
sequence is strongly conserved from zebrafish to humans.
MALAT1 has been linked to alternative splicing and
epigenetic regulation (Tripathi et al., 2010; Yang et al.,
2011b). MALAT1 was initially identified in nonsmall cell
lung cancers as a prognostic marker of survival (Ji et al.,
2003). However, loss of MALAT1 did not affect alternative
splicing or cell cycle progression, (Gutschner et al., 2013);
instead, MALAT1-deficient cells were impaired in cell
migration and defective in forming metastatic tumor
nodules. Surprisingly, loss of function mouse models did
not generate a significant phenotype (Zhang et al., 2013a).
HOTAIR (HOX antisense intergenic RNA) itself is
derived from mammalian the HOXC homeotic cluster
and can regulate HOXD (on a different chromosome)
expression. HOTAIR also operates in trans as part of a
structural scaffold by bridging chromatin with chromatinmodifying proteins, especially with the polycomb
repressive complexes (Nahkuri and Paro, 2012). Owing
to this function, HOTAIR overexpression in cancer leads
to genome-wide changes in the chromatin-modifying
complex binding sites. Interestingly, HOTAIR expression
was recently reported to be inversely correlated with
miR-141 expression in renal carcinoma cells (Chiyomaru
et al., 2014). In essence, HOTAIR promotes malignancy,
including proliferation and invasion, whereas miR-141
functions as a tumor suppressor. This inverse correlation
is due to direct binding of miR-141 to HOTAIR in
a sequence specific manner, supressing HOTAIR
expression and functions including proliferation and
invasion. Moreover, HOTAIR is overexpressed in breast,
colorectal, hepatocellular, gastrointestinal, and pancreatic
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carcinomas (Beckedorff et al., 2013a). These findings are
also important to question the interactions of noncoding
RNAs and microRNAs, further complicating our current
understanding of microRNAs and their targets.
XIST is another lncRNA that contributes to nuclear
compartmentalization and propagation of H3K27
methylation on the inactivated X chromosome (Xi), from
which Xist is transcribed to equalize gene expression
between the sexes. H3K27 methylation is a common
histone modification directing silencing. Interestingly,
Xist-deficient mouse hematopoietic stem cells show
aberrant maturation and age-dependent loss, leading
to highly aggressive myeloproliferative neoplasm and
myelodysplastic syndrome (Yildirim et al., 2013). TSIX
is another lncRNA that is transcribed from the opposite
strand of Xist to repress Xist, leading to DNA methylation
of the Xist promoter (Ohhata et al., 2011).
2.1.3. Intronic lncRNAs
lncRNAs that reside in introns of protein-coding genes
are called intronic lncRNAs. Sequences encoded within
introns appear to host an unexplored reservoir of novel,
functional RNAs known as sno-lncRNAs and antisense
intronic lncRNAs (St Laurent et al., 2012). While the
majority of lncRNAs are found within intergenic regions,
these intronic lncRNAs [no 5′ cap and no 3′ poly(A) tail]
originate from excised introns. Although it is generally
accepted that most of the excised introns or intron
fragments are degraded after splicing, this observation may
not hold true for some that are longer than 200 nucleotides
and that could accumulate to high levels in cells (Yang et
al., 2011a). It appears that these spliced intronic sequences
that reside in the nucleus have important roles as they
harbor functional noncoding regions. We already know
that a large number of snoRNAs are encoded within such
intronic regions (Filipowicz and Pogacic, 2002). Recently
it became clear that some intronic regions harboring 2
snoRNAs are processed from their ends by the snoRNP
machinery after splicing, but the internal intronic
sequences between snoRNAs are not removed, leading to
the accumulation of lncRNAs with snoRNA ends (snolncRNAs). Such RNAs appear to be widely expressed in
cells. An abundant class of sno-lncRNAs (15q11–q13) is
found to be deleted in Prader–Willi syndrome, and these
sno-lncRNAs are associated strongly with Fox family
splicing regulators and alter patterns of splicing (Yin et
al., 2012). Given these roles, deregulated expression of
host genes and therefore of spliced intronic regions that
harbor snoRNAs may have consequential effects on gene
regulation in many aspects in cancer cells.
sno-independent cases of antisense intronic lncRNAs
exist as well. RASSF1A (Ras association domain family
1 isoform A) is a tumor-suppressor gene shown to
control cell proliferation in several tumors. ANRASSF1
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is an antisense intronic lncRNA that is transcribed from
the opposite strand of the RASSF1 gene. Expression of
RASSF1A and ANRASSF1 follows an opposite pattern in
cancer cells. ANRASSF1 forms an RNA/DNA hybrid and
recruits chromatin-modifying enzymes to the RASSF1A
promoter, reducing the expression of RASSF1A and
increasing cell proliferation (Beckedorff et al., 2013b).
2.2. Upstream/enhancer RNAs
The discovery that enhancer regions upstream of coding
genes are transcriptionally active themselves was an
astonishing finding in terms of understanding genomic
complexity. Moreover, transcription from enhancer regions
seems to be evolutionarily conserved, suggesting vital roles.
Convincing evidence for the function of enhancer region
transcripts comes from knockdown of specific lncRNAs
(Orom et al., 2010). When specific lncRNAs are depleted,
neighboring genes’ expressions were also downregulated.
Such effects of lncRNAs can also be classified as a
positive cis action where lncRNA-mediated enhancer–
promoter looping occurs. Interesting studies revealed that
genome-wide upregulation of estrogen induced lncRNAs
positioned at enhancer sites/estrogen receptor binding
sites of estrogen-responsive genes (Hah et al., 2013; Li et
al., 2013). Similarly, PRNCR1 and PCGEM1 are 2 lncRNAs
that are required for the activation of androgen receptor
in prostate cancer cells. These lncRNAs are overexpressed
in many aggressive prostate cancers, aiding androgendependent cell proliferation (Yang et al., 2013). Such
enhancer-derived noncoding RNAs seem to enhance
transcriptional potential of genes by creating a permissive
chromatin structure and/or physically interacting with
activator proteins. These findings provide insight into how
enhancer sites may have an influence on the promoter and
eventually on gene expression. Therefore, not surprisingly,
deregulated expression of such RNAs may have significant
consequences on gene expression patterns.
2.3. Noncoding competing endogenous RNAs
Noncoding competing endogenous RNAs (ceRNAs)
are hypothesized to act as microRNA sponges (Salmena
et al., 2011). It is indeed plausible to assume coding and
noncoding RNA targets to crosstalk through their ability
to compete for miRNA binding sites. Experimental
evidence comes from PTEN and its pseudogene, PTENP1.
Several binding sites for miRNAs that target PTEN are
also found in the 3’-UTR of PTENP1 mRNA. It turns
out that the pseudogene PTENP1 can regulate PTEN and
exert a growth-suppressive role by acting as a miRNA
binding decoy (Poliseno et al., 2010). Further examples
support these findings. LncRNA HULC is one of the
upregulated genes in hepatocellular carcinoma (Panzitt
et al., 2007). CREB (cAMP response element binding
protein) is involved in the upregulation of HULC (Wang
et al., 2010). HULC may act as an endogenous ‘sponge’,

which downregulates miRNA-372. This, in turn, leads to
increased levels of its target gene, which can then induce
the phosphorylation and activation of CREB as part of an
autoregulatory loop.
Another example is Lethe, a pseudogene lncRNA. Lethe
is transcribed by NF-kB, a transcription factor important
in inflammation. In turn, Lethe binds directly to NF-kB
and inhibits NF-kB DNA binding activity. These findings
suggest that Lethe functions as a decoy, possibly to control
the strength of the inflammatory response by directly
interacting with the transcription factor (Rapicavoli
et al., 2013). Another class of lncRNAs, circular RNAs
(circRNAs, discussed below), can also be considered as
ceRNAs as they also harbor miRNA binding sites.
2.4. Transcribed ultraconserved regions
Transcribed ultraconserved region (T-UCR) transcripts are
a novel class of lncRNAs that are transcribed from regions
of the genome that can be considered as ultraconserved
regions (UCRs). These regions were discovered upon the
completion of genome sequencing of different species. It
turns out, interestingly, that approximately 500 regions,
UCRs, were found to be conserved (100% identity with no
insertions or deletions) between the orthologous regions
of the human, rat, and mouse genomes. These regions
are considered as mutational cold spots. Furthermore,
significant underrepresentation of single-nucleotide
polymorphisms (SNPs) within UCRs also confirms their
evolutional and functional importance (Katzman et al.,
2007; Yang et al., 2008). These genomic elements are
longer than 200 bp (range: 200–779 bp), generally map to
fragile sites, and can be intergenic, intronic, exonic, partly
exonic, and exon-containing. Given their enrichment in
cancer-associated genomic instability sites, genome-wide
profiling revealed that T-UCRs have distinct expression
signatures in different cancers with prognostic correlation
(Calin et al., 2007; Scaruffi, 2011). Hypermethylation
of T-UCR CpG islands has also been reported in colon
cancer, breast cancer, lung cancer, melanomas, leukemias,
and lymphomas (Lujambio et al., 2010). While the high
homology implies a conserved function, we are far from
understanding the functions of T-UCRs. Based on current
findings, there are certain functions attributed to T-UCRS,
such as long-range enhancer activity, transcriptional
regulation, splicing, and epigenetic regulation (Scaruffi,
2011). Understanding the roles of T-UCRs within these
and potentially other contexts could pave the way for
a better understanding of normal and cancer-related
regulatory mechanisms.
2.5. Circular RNAs
circRNAs can form naturally occurring circular structures
that attract much attention because of their ability to bind
and sequester miRNAs to abolish the repression of target
mRNAs. circRNAs form by head-to-tail circularization of
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exons with covalently joined ends (Memczak et al., 2013)
or from lariat introns (Zhang et al., 2013b). Recent studies
have suggested interesting roles of these circRNAs in gene
expression. One example is exonic CDR1as (antisense to
cerebellar degeneration-related protein 1), also known as
CIRS7. CDR1as is predominantly expressed in the brain
and has more than 70 miRNA binding sites; thus, CDR1as
was categorized as a miRNA sponge (Hansen et al., 2013).
CDR1as strongly suppresses miR-7 activity, resulting in
increased levels of miR-7 targets. Testis-specific circRNA,
sex-determining region Y (Sry), also serves as a miR138 sponge, suggesting that the miRNA sponge effects
achieved by circRNA formation may be a widely utilized
system in cells (Hansen et al., 2013). However, intronderived circRNAs are interestingly less likely to harbor
miRNA binding sites; they accumulate in the nucleus and
interact with RNA polymerase II (Zhang et al., 2013b).
Therefore, they may have transcriptional roles other than
recruitment of miRNAs.
3. Small noncoding RNAs
3.1. piwiRNAs (piRNAs)
piRNAs are small RNAs of 24–32 nucleotides long that
are Dicer-independent and generally bind to PIWI
proteins (a subfamily of argonaute proteins). piRNAs
and PIWI proteins are known for their protective role in
genome stability maintenance in germ lines (Brennecke
et al., 2007). piRNAs are transcribed from regions that
harbor expressed transposable elements. piRNAs and
PIWI form complexes to recognize these transcripts
and direct their cleavage. For a long time, piRNAs were
considered to be germline-specific defense elements for
transposable elements, especially when PIWI depletion
led to increased transposable element activity (Siomi et al.,
2011). Surprisingly, PIWI is also expressed in somatic cells
while nongermline-specific piRNAs have been described
in genome rearrangement and epigenetic programming,
with biological roles in stem-cell function, whole-body
regeneration, memory, and possibly cancer (Ross et al.,
2014). Interestingly, PIWI proteins have been implicated in
DNA methylation as well, pointing to a role in epigenetic
regulation (Esteller, 2011). In support of this, a piRNA was
implicated in DNA methylation of an imprinted mouse
locus (Watanabe et al., 2011).
In addition to normal physiological roles, cancerrelated findings are also intriguing. For example, somatic
LINE1 element-induced insertional mutagenesis has
been described in various epithelial cancers (Lee et
al., 2012). Such insertions tend to occur in commonly
mutated cancer genes that may serve for tumorigenesisrelated events in transformed cells. Accordingly, PIWI
increases in these situations may have a suppressive and
protective role. Indeed, PIWI expression has been studied
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in various somatic cancers and was proposed as a potential
biomarker. In other cases, PIWI overexpression (PIWIL2)
leads to antiapoptotic signaling and cell proliferation
(Esteller, 2011). It is clear that further research is needed
to delineate the PIWI expression deregulation in cancers
and whether it has any causative or protective roles. PIWI
proteins have also been implicated in stem-cell renewal
mechanisms (Ross et al., 2014).
Recently, mature piRNAs and PIWI proteins were
detected in cancer cell mitochondria (Kwon et al.,
2014). Further experiments are going to be exciting for
investigation of the role of the piRNA-PIWI pathway in
mitochondria in connection with cancer and possibly
altered metabolic pathways and/or oxidative stress
conditions.
3.2. microRNAs
miRNAs are small noncoding RNAs of 19–25 nucleotides
long that inhibit the translation and/or stability of mRNAs
by binding to 3’-UTRs. Based on the explosive number
of studies in the literature, we know that miRNAs are
involved in various different processes including cellcycle regulation, differentiation, inflammation, apoptosis,
and migration, mainly by controlling gene expression.
Regulatory roles of miRNAs have been shown in almost
all signaling pathways; consequently, dysregulation of
miRNAs has been implicated in the development of
human diseases including cancer.
miRNA genes are distributed throughout the genome,
either between protein-coding genes (intergenic) or in
their introns (intragenic). Almost all of the miRNA genes
are transcribed by RNA polymerase II (Pol II) (Lee et al.,
2004), possessing a 5’ cap and a 3’ poly(A) tail (Cai et al.,
2004). Still, a small group of Alu repeat-associated miRNAs
have been shown to be transcribed by RNA polymerase III
(Pol III) (Borchert et al., 2006).
miRNA biogenesis is a multistep enzymatic process
that starts in the nucleus and ends in the cytoplasm.
First, Pol II transcribes the miRNA gene into pri-miRNA
(primary miRNA). These are transcripts of several
kilobases long, which are characterized by stem-loop
structures harboring the mature miRNA. In the nucleus,
pri-miRNAs are cotranscriptionally recognized by the
Microprocessor complex (Gregory et al., 2004; Han et
al., 2004). The main components of the Microprocessor
complex, the Drosha/DGCR8 heterodimer crops the primiRNAs into pre-miRNAs (precursor miRNAs), which
are long hairpin structures of 60–100 nucleotides (Han
et al., 2004). DGCR8 is an RNA binding protein that is
responsible for pri-miRNA hairpin recognition, while
Drosha is an RNase III enzyme cropping the pri-miRNA.
Next, Exportin-5 and its partner Ran-GTP recognize premiRNAs from their ~2 nt 3’ overhangs and transport them
to the cytoplasm (Yi et al., 2003). In the cytoplasm, another
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RNase III, Dicer, recognizes pre-miRNAs and cleaves them
into ~22 nt long miRNA/miRNA* duplexes (Hutvagner et
al., 2001; Lee et al., 2003). When miRNA duplexes interact
with argonaute (Ago) proteins, the RNA-induced silencing
complex (RISC) is formed. RISC usually binds to the 3’UTR of target mRNAs by recognizing specific sequences
called “seed sequences” with partial complementarity.
RISC binding to the 3’-UTR causes either cleavage or
translational repression of the mRNAs. In addition to
canonical miRNA 3’-UTR targeting, some discrepancies
have been reported, such as miRNAs binding to 5’-UTR
of the mRNA to increase target gene translation (Orom et
al., 2008).
3.2.1. miRNAs and cancer
miRNAs have been implicated in cancer development
and progression since their discovery. Currently, it is well
known that miRNAs can be upregulated or downregulated
in numerous cancers (Erson and Petty, 2008; Selcuklu
et al., 2009). When miRNAs are downregulating tumor
suppressor genes, they function as oncogenes/oncomiRs.
On the other hand, they are called tumor-suppressor
miRNAs when they are targeting oncogenes. Important
regulatory roles of miRNAs have been implicated to
affect all 6 hallmark capabilities of cancer (Hanahan
and Weinberg, 2011) including sustaining proliferative
signaling, evading growth suppressors, activating invasion
and metastasis, enabling replicative immortality, inducing
angiogenesis, and resisting cell death. However, miRNAs
are also implicated in 2 emerging hallmarks: deregulating
cellular energetics and avoiding immune destruction.
Sustaining proliferative signaling and evading growth
suppressors are 2 fundamental hallmarks of tumorigenesis.
In normal cells, homeostasis is preserved by controlling
both mitogenic growth signals and antiproliferative signals.
When miRNA profiles are altered in cancer cells, cell cycle
regulators that are targeted by those miRNAs are also
deregulated. For instance, the let-7 family of miRNAs has
been shown to inhibit the RAS oncogene (Johnson et al.,
2005). Loss of let-7 expression has been linked to increased
expression of RAS and progression of acute myeloid
leukemia (Garzon et al., 2008) and lymphocytic leukemia
(Marton et al., 2008). Evasion of apoptosis is another
hallmark of cancer. MiRNAs are able to repress or induce
apoptosis by targeting proapoptotic or antiapoptotic genes,
respectively. MiR-21 is an oncomiR that is overexpressed
in almost all human cancers (Kumarswamy et al., 2011; Li
et al., 2012) . MiR-21 targets apoptotic genes such as PTEN
(Meng et al., 2007), and PDCD4 (Asangani et al., 2008),
thus preventing programmed cell death, apoptosis.
Besides interfering with apoptosis, cancer cells avoid
senescence and acquire a limitless replicative potential
either by homologous recombination events at telomeres
(Bailey et al., 2004) or by abnormal telomerase enzyme

activation (Davison, 2007). The role of miRNAs in this
scenario was revealed after expression levels of miR-138
were associated with telomerase deregulation (Mitomo
et al., 2008). According to this study, miR-138 inhibits
the human telomerase reverse transcriptase (hTERT)
gene, and thus loss of miR-138 leads to increased hTERT
in thyroid carcinomas. Another aspect of cancer cells
is that they are capable of producing high amounts of
proangiogenic factors to stimulate new blood vessel
formation. A number of miRNAs such as miR-126,
miR-378, and miR-296 have been named angioMiRs as
a result of their contribution to angiogenesis (Wang and
Olson, 2009). Vascular endothelial growth factor (VEGF)
levels, which are high in most tumors, are controlled at
multiple levels. In zebrafish, miR-126 was found to repress
negative regulators of the VEGF pathway, hence regulating
angiogenesis and vascular integrity (Fish et al., 2008).
Tumor invasion and metastasis is the leading cause
of morbidity and mortality in human cancers. A series
of complicated events including cellular detachment,
microenvironmental motility, and spread to distant organs
is orchestrated by various proteins (Chambers et al., 2002).
Involvement of miRNAs has been shown in various studies
showing miRNA’s effects on invasion and metastasis events
(Baranwal and Alahari, 2010). For instance, overexpression
of miR-10b has been shown in metastatic breast cancer
cases (Ma et al., 2007). In this case, increased expression
of miR-10b suppresses HOXD10 (homeobox D10) levels,
which leads to increased RHOC (Ras homolog gene
family, member C) levels, hence enhancing cells invasive
and metastatic abilities.
Hallmarks of cancer have been evolving as the
accumulating scientific data indicates the importance of
cellular processes in cancer such as cellular energetics and
avoidance of immune destruction. As with the previous 6
hallmarks, these newly emerging ones are also complicated
with miRNA regulations. Evasion of immune surveillance
by numerous strategies has been shown to be an ability of
cancer (Curtale and Citarella, 2013). For example, miR155 has been shown to an important regulator of immune
system function (Rodriguez et al., 2007). MiR-155 regulates
cytokines, chemokines, and transcription factors, which
are necessary for normal immune function (Rodriguez et
al., 2007). miRNA regulation during immune responses
in cancer is also of great interest (Pedersen and David,
2008). For instance B7-H3, a surface immune-modulatory
protein, inhibits natural killer cells and T cells. In normal
tissues, expression of miR-29 decreases B7-H3 protein
levels (Xu et al., 2009). However, miR-29 is downregulated
in solid tumors such as sarcomas and neuroblastomas, such
that B7-H3 protein levels are increased. The correlation
between low miR-29 levels and B7-H3 expression has
implications in immune system evasion of solid tumors.
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Finally, cancer cell metabolism has gained attention
with another cancer hallmark in recent years. As the
existence of a metabolic switch in cancer cells is known,
involvement of microRNAs has also been investigated. For
example, miR-378 has been implicated in a metabolic shift
in breast cancer cells by inhibiting expression of ERRγ
(estrogen-related receptor γ) and GABPA (GA-binding
protein α), thus causing reduction in TCA cycle gene
expression and oxygen consumption leading to cellular
proliferation (Eichner et al., 2010).
As exemplified in all hallmarks of cancer, regulatory
roles of miRNAs in cancer development and progression
are substantial. Therefore, therapeutics strategies regarding
inhibition or mimicking miRNAs are being investigated
for treatment of human diseases including cancer (Ling et
al., 2013; Nana-Sinkam and Croce, 2013). The first cancertargeted miRNA drug, MRX34, is a liposome based miR-34
mimic that entered phase I clinical trials for hepatocellular
carcinoma treatment (Bader, 2012; Bouchie, 2013). Mir34 has been shown to be a tumor-suppressor miRNA as
it regulates multiple oncogenes such as BCL2, cyclin D1,
and MYC, which are involved in the regulation of the
cell cycle, proliferation, antiapoptosis, metastasis, and
chemoresistance (Bader, 2012). Mir-34 is downregulated
in hepatocellular carcinomas; hopefully this replacement
strategy will display potential therapeutic applications for
miRNAs.
Taken together, additional research on novel miRNAs
and their targets will enhance our knowledge of the roles
of these regulators and hopefully these findings will speed
the development of diagnostic and therapeutic applications
for cancer. It is also worth noting that mRNAs can evade
miRNA binding by alternative polyadenylation at 3’-UTRs
(Sandberg et al., 2008; Akman and Erson-Bensan, 2014).
There is increasing evidence that some oncogenes may
switch to shorter 3’-UTRs to avoid microRNA regulation
in cancer cells (Mayr and Bartel, 2009; Akman et al., 2012).
3.3. snoRNAs/scaRNAs
Small nucleolar RNAs (snoRNAs) and small Cajal
body-specific RNAs (scaRNAs) are noncoding RNAs
involved in the maturation of other RNA molecules.
Small nucleolar RNAs (snoRNAs) are a class of small
RNA molecules (60–300 bp) that are components of
small nucleolar ribonucleoproteins (snoRNPs) to modify
rRNA precursors during their maturation for ribosome
assembly. These posttranscriptional modifications are
either 2′-O-methylation by the C/D box snoRNAs or
pseudouridylation by the H/ACA box snoRNAs in the
nucleolus where ribosomes are formed. Several hundred
snoRNAs have been mapped to intronic regions where
they are processed by exonucleolytic trimming (Zhang et
al., 2013b).
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It is clear that cells must coordinate ribosomal
biogenesis with other cellular processes including cell
proliferation. Not surprisingly, hyperactive ribosomal
biogenesis has been implicated as a feature of cancer
cells (Ruggero and Pandolfi, 2003). Initial studies also
suggested a potentially direct link between snoRNAs
and cancer. For example, h5sn2, a H/ACA box snoRNA,
was found to be significantly downregulated in human
meningiomas compared with normal brain tissues
(Chang et al., 2002). Later, several studies addressed the
significance of genomic instability regions that harbor
snoRNA genes in various cancer types (Mannoor et al.,
2012). Furthermore, deregulated expression of snoRNAs
along with small nucleolar ribonucleoprotein, fibrillarin,
in murine and human breast cancer appears to be critical
for tumorigenicity both in vitro and in vivo (Su et al.,
2014).
On the other hand, scaRNAs can modify snRNAs that
mediate mRNA splicing. Deregulated expression of both
snoRNAs and scaRNAs has been documented in various
cancer types (Ronchetti et al., 2013; Lawrie et al., 2014).
Altered sno/scaRNAs expression and its consequences in
terms of disease pathology are of future interest.
3.4. Endogenous small interfering RNAs (endo-siRNAs)
Initially, nematodes and Drosophila were demonstrated
to have a well-defined endo-siRNA pathway. Deepsequencing small RNA analysis helped the discovery
of mammalian/human endo-siRNAs that are ssRNAs
of 20 nucleotides long that originate from endogenous
dsRNAs such as antisense transcripts (cis- or trans-NATs),
transposable elements, and hairpin RNA transcripts
to repress either transposable elements or endogenous
mRNAs (Okamura et al., 2008; Okamura and Lai, 2008).
Interestingly, a subset of differentially expressed endosiRNAs that directly regulate LINE-1 expression is depleted
in human breast cancer cells compared to normal breast
cells. These endo-siRNAs seem to regulate endogenous
LINE-1 expression through increased DNA methylation
of the LINE-1 5’-UTR promoter (Chen et al., 2012). Global
mechanisms to regulate production of such endo-siRNAs
and consequences of deregulated production of endosiRNAs remain to be investigated in cancer cells.
3.5. rasiRNAs (repeat-associated small interfering RNAs)
rasiRNAs have been identified in plants, fission yeast,
Drosophila, and zebrafish. In mammals, rasiRNAs have not
been specifically described. Hence a link between cancer
and rasiRNAs has not been established yet. RasiRNAs
are thought to have roles in gene silencing of repetitive
sequence elements and transposable elements. RasiRNAs
are most abundant in testes and early embryos, where
regulation of transposon activity is critical and chromatin
modeling occurs (Aravin et al., 2003).
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4. Conclusion
With the advancements of sequencing and high throughput
analyses, we now better appreciate the significance of the
noncoding part of our genome. The long undervalued
noncoding transcripts are indeed quite abundant in cells
performing various functions. Not only these functions
but also how they interact with other noncoding RNAs,
coding RNAs, and DNA is interesting to observe. These
intertwined relationships will definitely provide a better
understanding of the complexities of our cells. A better
perspective on these normal events will then help us
improve our knowledge on disease states, mainly cancer,
where genomic instability and deregulated expression
of genes is common. Hence, noncoding RNAs carry the
potential for diagnostic and/or therapy strategies once their
gene structures, expression profiles, and specific functions
are better delineated. miRNAs are already considered as
valuable biomarkers in certain tissue types/cancer types
given their specific expression profiles in normal and cancer

cells. Based on current evidence, at least some noncoding
RNAs appear to have significant functions during gene
expression, development, and differentiation. Consequently,
their deregulation is highly associated with disease states.
For example, there are clinical trials pursuing the use of
noncoding RNAs in determining the predisposition to
specific cancers. For the future, noncoding RNAs will
not only be considered as biomarkers but also as targets
for therapy. Such therapy approaches may utilize RNAi,
aptamers, ribozymes, and small molecule drugs to target
deregulated noncoding RNAs. It appears these and other
novel approaches will be of great interest not only for cancer
but other diseases such as cardiovascular and neurological
diseases. Hopefully a comprehensive understanding of the
genome and transcriptome will be the key to advances in
such applications.
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